absTRaCT Gut-derived hormones, such as glucagon-like peptide-1 (GLP-1), have been proposed to relay information to the brain to regulate appetite. GLP-1 receptor agonists, currently used for the treatment of type 2 diabetes (T2DM), improve glycaemic control and stimulate satiety leading to decreases in food intake and bodyweight. We hypothesised that food intake reduction following GLP-1 receptor activation is mediated through appetite-and reward-related brain areas. Obese T2DM patients, normoglycaemic obese and lean individuals (n=48) were studied in a randomised, crossover, placebo-controlled trial. Using functional MRI we determined the acute effects of intravenous administration of the GLP-1 receptor agonist exenatide, with or without prior GLP-1 receptor blockade using exendin9-39, on brain responses to food pictures, during a somatostatin pancreatic-pituitary clamp. Obese T2DM patients and normoglycaemic obese vs.
absTRaCT
Gut-derived hormones, such as glucagon-like peptide-1 (GLP-1), have been proposed to relay information to the brain to regulate appetite. GLP-1 receptor agonists, currently used for the treatment of type 2 diabetes (T2DM), improve glycaemic control and stimulate satiety leading to decreases in food intake and bodyweight. We hypothesised that food intake reduction following GLP-1 receptor activation is mediated through appetite-and reward-related brain areas. Obese T2DM patients, normoglycaemic obese and lean individuals (n=48) were studied in a randomised, crossover, placebo-controlled trial. Using functional MRI we determined the acute effects of intravenous administration of the GLP-1 receptor agonist exenatide, with or without prior GLP-1 receptor blockade using exendin9-39, on brain responses to food pictures, during a somatostatin pancreatic-pituitary clamp. Obese T2DM patients and normoglycaemic obese vs.
lean subjects showed increased brain responses to food pictures in appetite-and reward-related brain regions (insula and amygdala). Exenatide vs. placebo decreased food intake and foodrelated brain responses in T2DM patients and obese subjects (in insula, amygdala, putamen and orbitofrontal cortex). These effects were largely blocked by prior GLP-1 receptor blockade using exendin9-39. Our findings provide novel insights into the mechanisms by which GLP-1 regulates food intake and how GLP-1 receptor agonists cause weight loss.
inTRoduCTion
The global rise in obesity and type 2 diabetes (T2DM) prevalence is a major public health problem (1;2). It has been hypothesised that excessive eating due to changes in central nervous system (CNS) satiety and reward responses to food underlies the development of obesity and T2DM, comparable to the role for altered CNS responses in drug addiction (3) . Several studies in obese individuals have demonstrated increased CNS responses to visual food-cues in areas involved in appetite and reward processing (insula, amygdala, orbitofrontal cortex (OFC) and striatum) (4) (5) (6) and this increased CNS food-cue responsiveness predicts future weight gain (7) . The mechanisms underlying these alterations in CNS responses to food-cues are not clear, but multiple metabolic and hormonal factors seem to be involved (8) (9) (10) .
Food ingestion activates the secretion of several gut-derived mediators, including the incretin hormone glucagon-like peptide-1 (GLP-1). GLP-1 stimulates meal-related insulin secretion, inhibits glucagon release and delays gastric emptying, all of which mechanisms contribute to its glucometabolic effects (11) . In addition, several observations suggest that GLP-1 has a role in the regulation of food intake. Systemic administration of GLP-1 reduced food intake in rodent and human studies (12) and blocking the GLP-1 receptor with exendin 9-39 resulted in hyperphagia and attenuated satiety after a meal in rodents (13) .
GLP-1-based therapies, including GLP-1 receptor agonists such as exenatide, are currently successfully employed in the treatment of patients with T2DM. GLP-1 receptor agonists improve glycaemic control and stimulate satiety, leading to reductions in food intake and body weight (14) . The mechanisms of the latter effects are as yet not fully understood, but GLP-1 receptor agonist actions on the brain may mediate satiety and weight effects in humans. In rodents, GLP-1 receptors are present in brain areas controling feeding behaviour and energy balance, such as the hypothalamus, nucleus tractus solitarii, area postrema, dorsal striatum and nucleus accumbens (15) . Recent additional data in rodents showed that central GLP-1 receptors are involved in the anorectic effects of GLP-1 receptor agonists (16) . In humans, using positron-emission tomography (PET), a statistical association was shown between post-prandial endogenous GLP-1 response and changes in neuronal activity of brain areas implicated in satiation and food intake regulation (dorsolateral prefrontal cortex and hypothalamus) (17) . However, interventional studies determining the central effects of GLP-1 receptor activation, independent of glucometabolic changes, have not been performed.
We hypothesised that GLP-1 receptor agonists reduce food intake by affecting brain areas regulating appetite and reward, and that these effects are GLP-1 receptor mediated and independent of other hormonal and metabolic changes. Therefore, we assessed the acute effects of intravenous exenatide, with or without prior GLP-1 receptor blockade with intravenous exendin 9-39, on food intake and CNS responses to visual food-cues using functional MRI (fMRI) in obese T2DM patients, normoglycaemic obese and lean individuals. In order to study the effects of GLP-1 receptor activation per se, i.e. independent of hormonal or metabolic changes induced by GLP-1 receptor activation, all measurements were performed during a somatostatin pancreatic-pituitary clamp.
ReseaRCh desiGn and meThods

Participants
After screening 79 individuals, we included 16 obese T2DM patients, 16 obese participants used antihypertensive medication, 13 T2DM patients and 1 obese participant used statins. In the T2DM group, 8 participants were treated with metformin monotherapy and 8 used metformin in combination with a sulphonylurea. The lean controls did not use any medication. Reasons for screen failure were: impaired glucose tolerance (n = 9), HbA1C not between 6.0-8.5% for patients with T2DM (n = 3), inability to undergo MRI scanning (n = 6), depressive symptoms (n = 1), incidental findings (n = 4), micro-albuminuria (n = 5), no accessible veins (n = 2) and no stable body weight (n = 1).
The study (NCT01281228) was approved by the Medical Ethics Committee of the VU University
Medical Center and was performed in accordance with the Helsinki Declaration. All participants provided written informed consent before participation.
experimental design
The study was a randomised, placebo-controlled, crossover study. Each participant underwent 3 fMRI sessions at separate visits (with at least 1 week between visits) in random order with intravenous infusion of 1) exenatide, 2) exenatide together with the GLP-1 receptor antagonist exendin 9-39, or
3) placebo ( Figure 1A ). The participants were blinded to the type of infusions. All visits commenced at 8:30 AM after an overnight fast and participants did not exercise or drink alcohol for 24 h before the sessions. Sulphonylureas were discontinued 3 days prior to examination and metformin was discontinued on the day of examination. In order to study the effects of GLP-1 receptor activation per se, i.e. independent of hormonal or metabolic changes induced by GLP-1 receptor activation, all measurements were performed during a somatostatin pancreatic-pituitary clamp according to principles previously described (20) . In short, somatostatin (Somatostatin; Eumedica) was infused at a rate of 60 ng/kg/min to suppress endogenous insulin, glucagon, growth hormone and GLP-1 production. Human glucagon (0.6ng/kg/min) (Glucagen; Novo Nordisk), growth hormone (2ng/ kg/min) (Genotropin; Pfizer) and insulin (0.6mU/kg/min) (Actrapid; Novo Nordisk) were infused at constant rates to achieve stable levels. Glucose (200 g/l) was infused at a variable rate to clamp plasma glucose at 5.0 mmol/l. Intravenous exendin 9-39 (Bachem; Clinalfa products, Switzerland)
or placebo was started 30 minutes after the start of the clamp at an infusion rate of 600 pmol/kg/ min (21) . Intravenous exenatide (Byetta; Eli Lilly) or placebo infusion was started 60 minutes after the start of the clamp at an infusion rate of 50 ng/min for 30 minutes, and was decreased to 25 ng/min for the remaining time of the clamp procedure (22) . Each peptide was diluted in saline containing 0.5% human serum albumin and was infused using a separate MRI-compatible infusion pump (MRidium 3850 MRI IV pump, Iradimed, Winter Park, USA). Participants assumed the reclining position and a catheter was inserted into a cubital vein for infusion of glucose and clamp hormones, and for the infusion of exenatide and/or exendin 9-39 or saline. A second catheter was inserted into a contralateral cubital vein for blood sampling. This arm was kept in a heated box (50°C) throughout the experiment to arterialize the venous blood. During the MRI-session, a MRI-compatible heated box was used. Plasma glucose was measured every 10 minutes. Blood for measuring insulin, glucagon and exenatide levels was drawn every 30 minutes. Blood for measuring growth hormone, free fatty acids and cortisol was drawn at t = 0 minutes (fasting) and t = 120 minutes (during the fMRI session).
Questionnaires
At 5 time points (beginning of the experiment, before and after the MRI scan, before and after the ad libitum lunch) participants were asked to rate their hunger, fullness, appetite, prospective food consumption, desire to eat and feelings of nausea on a 10-point Likert-scale (23) . Participants also filled out the shortened version of the profile of mood state (POMS) at the beginning of the experiment and after the MRI scan (24) .
fmRi paradigm
The fMRI task consisted of 126 pictures within 3 categories: 1) high calorie food, 2) low calorie food and 3) non-food, adapted from previous studies (6;25 each of high calorie foods, low calorie foods and neutral pictures. The blocks were separated by 9 seconds of grey blank screen with a fixation cross. The order of blocks was randomised with the constraint that a given picture category was not followed by the same category.
GH growth hormone; Cal calorie.
Inc., Pittsburg, PA). Pictures were presented in a block design format, with a total of 3 runs. Each run consisted of 6 blocks of pictures: 2 blocks of high calorie foods, 2 blocks of low calorie foods and 2 blocks of non-food pictures ( Figure 1B ). Within each block of 21 seconds, 7 individual pictures were presented for 2.5 seconds each followed by a 0.5 second gap each. The blocks were separated by 9
seconds of grey blank screen with a fixation cross. The order of blocks was randomised from run to run with the constraint that a given picture category was not followed by the same category. Pictures were matched across blocks and sessions for shape and colour. Since each participant was scanned 3 times, 3 versions with different pictures but otherwise identical design were created. The sequences of blocks were randomised across study visits. Participants were instructed to watch all pictures and to try to remember them for a recognition test. After the measurements, participants were given a recognition test consisting of 20 laminated colour food and non-food pictures (10 pictures of the MRI task randomly intermixed with 10 novel pictures).
image acquisition and analysis MRI data were acquired on a 3.0 Tesla GE Sigma HDxt scanner (General Electric, Milwaukee, Wisconsin, USA). A 3D structural MRI was obtained using a T1-weighted sequence. fMRI data were acquired using an echo planar imaging T2* Blood Oxygen Level Dependent (BOLD) pulse-sequence Functional images were analysed with SPM8 software (Wellcome Trust Centre for Neuroimaging, London, UK). The origin of each MR volume was aligned to the anterior commissure. Series were corrected for differences in slice acquisition times and were realigned to the first volume. T1-coregistered volumes were normalised to Montreal Neurological Institue (MNI) space, resliced to 3 x 3 x 3 mm voxels and spatially smoothed using an 8 mm full width at half maximum Gaussian kernel.
After high-pass filtering (cut-off 128 second) to remove low-frequency noise, functional scans were analysed in the context of the general linear model. At the first level each block of high calorie food, low calorie food and non-food was modelled using boxcar functions convolved with the canonical haemodynamic response function. For each subject and for each condition, contrast images were computed (all food pictures vs. non-food pictures; high calorie food pictures vs. non-food pictures).
These first-level contrast images were entered into 2 separate second-level, random-effects
ANOVAs to assess between-and within-group differences. To determine if changes in neuronal reponse (placebo vs. exenatide) were related to changes in caloric intake (placebo vs. exenatide) we performed a regression analysis in SPM using the change in caloric intake as a covariate of interest.
A priori ROIs were determined based on previous studies (i.e. insula, striatum, amygdala and OFC) (4) (5) (6) . Only significant brain activations that survived family-wise error (FWE) correction for multiple comparisons on the voxel level within the ROIs using a small volume correction (SVC), or across the entire brain for regions not a priori of interest, are reported. SVC was performed using 5 mm (for amygdala) or 10 mm (for insula, putamen and OFC) radius spheres (26;27).
Ad libitum lunch buffet
After the MRI session, while all infusions continued, participants were presented a varied choice buffet to assess energy intake (28) . Participants were advised to eat as much as they wanted. They
were not aware that their choices and food intake were being monitored. After 30 minutes the buffet was taken away and the total kilocalories consumed and the percentages of kilocalories derived from fat, carbohydrates and protein were being calculated.
assays
Blood glucose was measured immediately after sampling using the glucose dehydrogenase method (Glucose Analyzer, HemoCue, Ängelholm, Sweden). All other blood samples were stored at -80°C until assay. Insulin levels were determined using an immunometric assay (Advia, Centaur, Siemens Medical Solutions Diagnostics, USA). Growth hormone levels were determined using a chemiluminescence immunoassay (Liaison Diasorin, S.p.A, Italy). NEFA levels were measured with an enzymatic colorimetric method (Wako Chemicals GmbH, Neuss, Germany). Cortisol levels were determined using a competitive assay (Advia, Centaur, Siemens Medical Solutions Diagnostics, USA).
Glucagon levels were measured using an immunoassay (Lilly Research Laboratories, Indianapolis, USA). Exenatide levels were determined by an immunoenzymatic assay (Tandem laboratories, San Diego, USA), with a detection limit of 20 pg/ml.
statistical analyses
Clinical group data are expressed as mean ± SEM (unless otherwise stated) and were analysed with the Statistical Package for the Social Sciences (SPSS) version 20. Between-group differences in the placebo condition were analysed with ANOVA or, in case of more than 1 time point, with repeated measures ANOVA using time (minutes) as within-subject factor and group as between-subject factor.
Within-group differences were analysed using repeated measures ANOVA using treatment and time (minutes) as within-subject factor. In case of a significant result, a post-hoc Bonferroni multiple comparisons correction was used. In case of skewed data, Kruskal-Wallis test was used for betweengroup differences and Friedman test for within-group differences. In case of a significant result Mann-Whitney U-test for between-group analysis or Wilcoxon signed rank for within-group analysis with post-hoc Bonferroni correction was performed. P < 0.05 was considered statistically significant.
ResuLTs baseline characteristics
We included 16 obese T2DM patients, 16 normoglycaemic obese and 16 lean subjects; 47 subjects completed all 3 test days. One subject only completed the exenatide and placebo test day. Subjects in the 3 groups were age-and gender-matched, while T2DM patients and normoglycaemic obese subjects were also BMI-matched (Table 1) .
Plasma levels of hormones and metabolites during the pancreatic-pituitary clamp
During the fMRI session and ad libitum lunch (t=90 until t=180 min, Figure 1A ), blood glucose was successfully clamped at approximately 5.0 mmol/l, with no statistically significant differences in glucose levels between groups and between sessions within each group (Supplemental Table 1 , Supplemental Figure 1 ). As expected, the lean subjects needed higher glucose infusion rates in comparison to obese subjects and T2DM patients (P < 0.05), but infusion rates were not different between sessions within each group (Supplemental Table 1 , Supplemental Figure   1 ). During the clamp, insulin levels were higher in T2DM patients and obese in comparison to lean subjects (P < 0.001); glucagon levels were lower in obese in comparison to lean subjects (P < 0.05); NEFA levels were higher in T2DM patients as compared to lean and obese subjects (P < 0.006) (Supplemental Table 1 ). Due to the pancreatic clamp, there were no significant differences between sessions within each group in circulating hormones and metabolites (insulin, glucagon, growth hormone and non-esterified fatty acids (NEFA)) (Supplemental Table   1 , Supplemental Figure 2 ). There was a trend towards higher cortisol levels in the lean subjects *Statistically significant different from lean (post-hoc Bonferroni corrected P < 0.05) †Statistically significant different from lean and obese (post-hoc Bonferroni corrected P < 0.05) ‡Statistically significant different from obese (post-hoc Bonferroni corrected P < 0.05)
OGTT, oral glucose tolerance test; NEFA, non-esterified fatty acids; T2DM, type 2 diabetes patients during exenatide infusion in comparison to exenatide in combination with exendin 9-39 (P = 0.12). The infusion of exenatide resulted in pharmacologically relevant plasma concentrations that were similar in the lean, obese and T2DM group (181 ± 13, 154 ± 13 and 153 ± 13 pg/ml respectively, P for between-group difference = 0.25) (29;30).
brain responses to food pictures in T2dm, obese and lean subjects
We investigated two main contrasts of interest, one to assess general food-related responses (all food pictures vs. non-food pictures) and a second to assess reward-related responses (high calorie food pictures vs. non-food pictures). Effects of these contrasts across all subjects are reported in Supplemental Table 2 . Obese vs. lean subjects showed increased brain activation in bilateral insula (all food vs. non-food and high-calorie vs. non-food) and right amygdala (all food vs. non-food) ( Figure 2A , Supplemental Table 3 ). T2DM patients vs. lean subjects showed increased brain activation in left insula (all food vs. non-food) ( Figure 2B , Supplemental Table 3 ).
Obese subjects vs. T2DM patients showed increased activation in right insula (all food vs. nonfood and high-calorie vs. non-food).
Pretreatment with the GLP-1 receptor antagonist exendin 9-39, largely blocked the exenatideinduced effects on brain activations, i.e. in obese subjects in right insula, amygdala and left OFC, and in T2DM patients in bilateral insula, left putamen and right OFC ( Table 2) .
GLP-1 receptor activation and brain responses to food pictures
Exenatide vs. placebo decreased brain activations in obese subjects in right amygdala and insula (all food vs. non-food), in right insula and left OFC (high-calorie vs. non-food) and in obese T2DM patients in bilateral insula, left putamen and right OFC (all food vs. non-food and high-calorie vs. non-food) ( Figure 3 , Table 2 ). Exenatide also decreased brain activations (all food vs. non-food) in the right putamen in the obese group and in the right amygdala in the T2DM group, but these effects were not statistically significant (P = 0.13 and 0.16, respectively; data not shown).
In the lean subjects we found no statistically significant effects of exenatide vs. placebo on brain activations (all food vs. non-food), although there was a trend towards attenuated activation in right insula, OFC and putamen (P = 0.18, 0.09, 0.22, respectively).
A recognition test was performed after all measurements to ensure that the subjects watched the pictures attentively during the fMRI session. There were no statistically significant differences in recognition test scores between groups and between sessions (data not shown). Results are presented at a threshold of P < 0.05, FWE corrected on the basis of cluster extent. In the graphs BOLD signal intensity (effect size) for the different test days is plotted (arbitrary units), mean and SEM. 
GLP-1 receptor activation, ad libitum food intake and hunger-scores
There was a significant difference between sessions in caloric intake in each group (P < 0.05), with reductions in intake during exenatide vs. saline infusion of 23% ± 8%, 23% ± 10%, 14%
± 5% in the lean, obese and T2DM group, respectively. These effects of exenatide were greatly reduced by concomitant infusion with the GLP-1 receptor antagonist exendin 9-39 ( Figure 4 ).
There were no significant differences between sessions in each group in the percentages of kilocalories derived from fat, carbohydrates and proteins.
We found a positive correlation between changes in caloric intake (placebo vs. exenatide) and changes in CNS responses (placebo vs. exenatide, for the food vs. non-food contrast) in T2DM patients in bilateral insula and right caudate nucleus, and in obese subjects in bilateral OFC, bilateral insula and right caudate nucleus (Supplemental Table 4 ). As expected, no significant correlation was found in lean subjects, since there were no significant effects of GLP-1 receptor activation on CNS responses to food pictures in this group.
We found no statistically significant differences between groups and between conditions in hunger, fullness, appetite, prospective food consumption, desire to eat and feelings of nausea.
In addition, no between-group or within-group differences in mood state, as assessed by the profile of mood state (POMS), were found (data not shown). Although there were no statistically significant differences in nausea scores before and directly after the lunch (P > 0.19), 3 subjects in the lean group and 2 in the obese group experienced nausea and vomiting on the exenatide test day after termination of all infusions and all measurements.
disCussion
In the present study we confirmed that normoglycaemic obese vs. lean subjects have increased activation in appetite-and reward-related brain areas in response to viewing food-cues (4;6;25), Bar chart with caloric intake in 3 groups during different infusions. Within-group differences were tested with repeated measures ANOVA (indicated by top line). Post-hoc tests were done by two-sample T tests with Bonferroni correction for multiple testing.
Data are presented as mean and SEM. **P < 0.005 ; * P < 0.05 ; T2DM, type 2 diabetes patients ; Ex9-39, exendin 9-39
and we expanded these observations by showing that obese T2DM patients have increased activation in the insula in comparison to lean subjects. Most importantly, using intravenous exenatide we found that GLP-1 receptor activation reduced brain responses to food-cues in normoglycaemic obese subjects and obese T2DM patients in appetite-and reward-related brain areas, correlating with reductions in food intake. The exenatide-induced effects were GLP-1 receptor mediated as these could be inhibited by infusion of the GLP-1 receptor antagonist exendin 9-39, and occurred independently of circulating metabolic and hormonal factors.
Our study provides novel insights into the mechanisms by which GLP-1 receptor agonists reduce food intake. In obese and T2DM subjects we observed effects of GLP-1 receptor activation on brain responses to food-cues in the insula, amygdala, OFC and putamen. These brain areas are assumed to be involved in the regulation of appetite and reward. The insula is involved in the processing of food-cues and craving for food (31) and has been implicated in the devaluation of food-cues when eating to satiety (32) . The amygdala plays a pivotal role in emotional learning and in the association of cues with reward (33) by encoding the value of the reward predicted by the conditioned stimuli (34) . The OFC and putamen are also implicated in reward processing (35) and the OFC is assumed to be involved in decision making (36) . Our findings are of interest since they are expanding findings from previous fMRI studies showing effects of leptin and the gut-derived hormones PYY and ghrelin on brain responses to food-cues in similar brain areas (8;9;37;38). In the search for therapeutic targets for the treatment of obesity, all of these hormones have been explored, but currently to no avail (39) . Interestingly, GLP-1-receptor agonists have shown modest but consistent weight loss in humans (14) .
In the lean subjects we also observed effects of GLP-1 receptor activation on food intake and brain responses to food-cues in several brain areas (insula, OFC, putamen), but the latter were not statistically significant. The lower brain activation in response to food-cues in lean individuals per se may have reduced the likelihood to find significant effects of GLP-1 receptor activation on these brain activations. A previous study in lean subjects also failed to observe significant effects of intravenous administration of GLP-1 alone on brain responses to food-cues, but co-infusion with the postprandial anorectic hormone PYY resulted in significant effects on appetite centers (38) . It should be pointed out that these measurements may have been influenced by GLP-1-or PYY-induced changes in circulating hormones and metabolites, such as glucose, insulin and glucagon. Since insulin and glucose modulate brain activity in areas controling feeding behaviour (10) , this may have confounded the measurements. In our study, all measurements were performed during a somatostatin pancreatic-pituitary clamp and were therefore independent of changes in circulating levels of glucose, insulin, glucagon and growth hormone. 82 We found that the effects of exenatide on food intake and brain responses to food-cues were largely inhibited by exendin 9-39, suggesting that the effects of exenatide are GLP-1 receptor mediated.
Whether the CNS effects of exenatide are mediated via central or peripheral GLP-1 receptors cannot be determined from our study. In rodents, it was shown that exendin-4 (a peptide closely resembling exenatide structurally) is able to cross the blood-brain barrier (40) GLP-1 has been shown to delay gastric emptying (45) and can induce nausea, which may also contribute to the satiety-inducing effects. However, reductions in appetite after GLP-1 administration are present in fasting subjects (with an empty stomach) (46) . In the current study subjects were also fasted during all measurements, and relevant effects on appetite-and reward-related brain areas were observed. Unfortunately, after the lunch when all infusions were terminated some subjects experienced nausea and vomiting, which may have been caused by exenatide-induced effects on gastric emptying. However, there were no significant effects of exenatide on nausea scores during the fMRI measurements and before and directly after the lunch. There are several other reasons to assume that delayed gastric emptying and nausea are not the only cause of reductions in food intake and body weight during GLP-1 receptor agonist treatment. The weight reduction seen during GLP-1 receptor agonist treatment is also observed in the absence of nausea (47) . Furthermore, the inhibitory effect of GLP-1 on gastric emptying is subject to tachyphylaxis (rapid desensitization) (48) , whereas the weight lowering effects persist over periods up to 3 year (49).
In contrast to previous studies (50), we found no statistically significant effects of GLP-1 receptor activation on scores of hunger, fullness, appetite, prospective food consumption and desire to eat. In subjects eating their normal diets in their normal environment, appetite scores have been shown to correlate with, but not reliably predict, energy intake to the extent that they could be used as a proxy of energy intake (51) . Under experimental conditions, such as those in our complex experimental fMRI study, appetite scores may be less sensitive (51) .
We demonstrated the acute effects of GLP-1 receptor activation on CNS responses to foodcues and food intake during a somatostatin pancreatic-pituitary clamp. As a consequence, our measurements were performed under non-physiological circumstances. Therefore it may be difficult to directly translate our results to e.g. clinical use of GLP-1 receptor agonists. However, the observed food intake suppressive effect of exenatide in our study is in line with studies using intravenous GLP-1 in a more physiological setting (12) and with observed weight loss during chronic treatment with GLP-1 receptor agonists (14) . Long-term studies using fMRI measurements of food-related CNS responses during chronic treatment with GLP-1 receptor agonists are of interest.
In summary, we found that the GLP-1 receptor agonist exenatide decreases hyperactivation in appetite-and reward-related brain regions, elicited by viewing food-cues in obese T2DM
and obese normoglycaemic subjects, thus restoring an activation pattern that more closely resembles that of lean individuals. We found that these effects are GLP-1 receptor mediated and independent of circulating metabolic and hormonal factors. Our findings provide novel Mean insulin levels (pmol/l) in lean (a), obese (b) and T2DM (C) subjects.
Mean glucagon levels (pmol/l) in lean (d), obese (e) and T2DM (f) subjects.
EXE, exenatide; EX9-39, exendin 9-39
Data are means ± SEM.
